2030 Compounding Vaccines 
Express Pharma
DECEMBER 11, 2024
The respiratory syncytial virus (RSV) prophylaxis market across the eight major markets (8MM*) is forecast to grow at a compound annual growth rate (CAGR) of 26.7 billion in 2030, with the pediatric and adult segments accounting for $2.2 Six more products in late-stage development have potential to launch by 2030.
European Pharmaceutical Review
JUNE 27, 2022
The Kigali Summit on Malaria and NTDs , hosted by His Excellency (HE) Paul Kagame, President of the Republic of Rwanda, on Thursday 23 June 2022, gathered world leaders to commit to ending these devastating diseases by the end of 2030. Did you know, 1.7 LXE408 is currently entering Phase II clinical development.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
NOVEMBER 7, 2024
A report by Azoth Analytics expects that globally, the single-use technology rocking bioreactors market will grow at a compound annual growth rate (CAGR) of 3.9 percent between 2025 and 2030. The report noted that last year, the cell culture sector held approximately 60 percent of the single-use technology rocking bioreactors market.
Pharmaceutical Technology
MAY 18, 2023
The World Health Organization (WHO) 2021 roadmap outlines plans to eradicate 20 listed diseases, which include leprosy, scabies and mycetoma, by 2030. Neglected tropical diseases are a major global health concern, affecting over 1.7 billion people, many of whom live in the poorest and most vulnerable communities.
Express Pharma
JULY 10, 2024
India has traced a journey of grit and glory to emerge as a major supplier of generic drugs and vaccines globally. Brimming with potential As per an Invest India report of 2023, the Indian Bioeconomy, valued at $137 billion in 2023, is targeted to reach $150 billion by 2025 and $300 billion by 2030. million and contributes around $1.4
Express Pharma
MAY 25, 2024
India’s pharmaceutical industry is on a promising path, with a vision to reach a staggering $130 billion by 2030 and $450 billion by 2047, according to a report by Ernst and Young. This growth is fueled by a thriving pharma industry that has already exported over 300 million vaccine doses as of July 2023 and impressive growth with $668.9
PharmaShots
APRIL 3, 2023
of the newly combined company The combined companies’ focus is to advance Elicio’s lymph node-targeting amphiphile technology to develop immunotherapies & also focus on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors is currently being evaluated in the P-I trial (AMPLIFY-201) for PDAC and CRC.
Expert insights. Personalized for you.
66 
Let's personalize your content